More New Cancer Facts in the News: If Your Patient Asks, Part II

The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026.

Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.

Noninferiority of FMT to standard-of-care would significantly reduce antibiotic use and well-known harms, including antibiotic resistance, study authors noted.

Discover the latest breakthroughs in clinical research, from at-home cancer screening to AI advancements in mammography, shaping future healthcare practices.

Solriamfetol's significant cognitive benefits may be the result of mechanisms operating independently of its wake-promoting effects, study authors suggest.

The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.